Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Zimmermann, Wolfram-Hubertus  [Clear All Filters]
Journal Article
Cavero I, Seimetz D, Koziel D, Zimmermann W-H, Holzgrefe HH. 19 Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin Drug Saf. 2020.
Schlick SF, Spreckelsen F, Tiburcy M, Iyer LM, Meyer T, Zelarayan LC, Luther S, Parlitz U, Zimmermann W-H, Rehfeldt F. Agonistic and antagonistic roles of fibroblasts and cardiomyocytes on viscoelastic stiffening of engineered human myocardium. Prog Biophys Mol Biol. 2018.
Yang T, Rubart M, Soonpaa MH, Didié M, Christalla P, Zimmermann W-H, Field LJ. Cardiac Engraftment of Genetically-Selected Parthenogenetic Stem Cell-Derived Cardiomyocytes. PLoS One. 2015;10(6):e0131511.
Zimmermann W-H. Challenges to Heart Repair with Pluripotent Stem Cell-Derived Cardiomyocytes. Trends Cardiovasc Med. 2020.
Zhao Z, Li X, El-Battrawy I, Lan H, Zhong R, Xu Q, Huang M, Liao Z, Lang S, Zimmermann W-H, et al. Drug testing in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1. Clin Pharmacol Ther. 2019.
Schoger E, Zimmermann W-H, Cyganek L, Zelarayán LCecilia. Establishment of a second generation homozygous CRISPRa human induced pluripotent stem cell (hiPSC) line for enhanced levels of endogenous gene activation. Stem Cell Res. 2021;56:102518.
Schoger E, Zimmermann W-H, Cyganek L, Zelarayán LCecilia. Establishment of two homozygous CRISPR interference (CRISPRi) knock-in human induced pluripotent stem cell (hiPSC) lines for titratable endogenous gene repression. Stem Cell Res. 2021;55:102473.
Schoger E, Argyriou L, Zimmermann W-H, Cyganek L, Zelarayán LCecilia. Generation of homozygous CRISPRa human induced pluripotent stem cell (hiPSC) lines for sustained endogenous gene activation. Stem Cell Res. 2020;48:101944.
Schmoll KAline, Mager T, Tse TPok-Man, Alameldeen A, Zimmermann W-H, Zafeiriou M-P. Genome engineering of a neuronal specific, optogenetic, induced pluripotent stem cell line. Stem Cell Res. 2024;75:103317.
Knauer C, Haltern H, Schoger E, Kügler S, Roos L, Zelarayan LC, Hasenfuss G, Zimmermann W-H, Wollnik B, Cyganek L. Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic variants. Mol Ther Nucleic Acids. 2024;35(1):102123.
Shahriyari M, Rinn M, Hofemeier AD, Babych A, Zimmermann W-H, Tiburcy M. Protocol to develop force-generating human skeletal muscle organoids. STAR Protoc. 2023;5(1):102794.
Jebran A-F, Tiburcy M, Biermann D, Balfanz P, Didié M, Karikkineth BChandapill, Schöndube F, Kutschka I, Zimmermann W-H. Transmural myocardial repair with engineered heart muscle in a rat model of heterotopic heart transplantation - A proof-of-concept study. J Mol Cell Cardiol. 2022.